Accordingly, PrPC over-expression in estrogen receptor (ER)-negative breast cancer patients is associated with a lower sensitivity to chemotherapy, thus suggesting that PrPC could be predictive for the benefit of adjuvant chemotherapy in ER-negative patients [56]. This evidence concerns the gene ESR1 and breast cancer.